World-leading capabilities in multiplexable gene editing
Join Our Team
Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Newsroom
Press Releases
Qihan Biotech Announces Multiple Presentations at the 2025 American Society of Hematology (ASH) Annual Meeting2025/11/03
At the upcoming 2025 ASH Annual Meeting, Qihan Biotech will present new data highlighting significant progress across its off-the-shelf and in vivo CAR-T cell therapy programs.
1 / 4Press Releases
Qihan Biotech Announces FDA Clearance of IND for QT-019B, a Universal Dual-Target CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus2025/08/13
The U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QT-019B.
1 / 4Press Releases
Qihan Biotech Appoints Tony W. Ho to its Board of Directors2022/10/16
Qihan Biotech today announced the appointment of Tony W. Ho, M.D., to its Board of Directors as an independent director.
1 / 4Press Releases
iPSC-CAR-NK Cell Therapy Clinical Results Published in Cell, Marking a Global Breakthrough in Autoimmune Disease Treatment2025/06/25
Qihan Biotech announced the publication of groundbreaking clinical results in Cell.
1 / 4
Contact Us
Hangzhou Qihan Biotech Co., Ltd.
Address: Xiaoshan District, Hangzhou, Zhejiang, China
Zipcode: 311200
TEL: 0571-83500380
FAX: 0571-83500370